Your SlideShare is downloading. ×
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & Results
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

P-OM3 trial - Summary & Results

227

Published on

http://www.theheart.org/web_slides/1171735.do …

http://www.theheart.org/web_slides/1171735.do

One of the largest studies to examine the effect of omega-3 polyunsaturated fatty acids (PUFA) on AF

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
227
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. P-OM3
  • 2. P-OM3PR Kowey (Lankenau Institute for medical Research, Wynnewood, PA)American Heart Association 2010 Scientific Sessions• One of the largest studies to examine the effect of omega-3 polyunsaturated fatty acids (PUFA) on AF• Population and treatment: 663 outpatients with documented symptomatic paroxysmal or persistent AF (n=542 and n=121, respectively) without significant structural heart disease and initially in sinus rhythm Randomized to receive placebo or the prescription omega-3 PUFA capsules (fish oil) at 8 g/day for the first seven days followed by 4 g/day for total of 24 weeks• Primary outcome: First recurrence of symptomatic AF or atrial flutter
  • 3. P-OM3: Results• Fish oil did not show an effect on the primary end point but there were trends toward a reduction in average ventricular rate during the first AF recurrence and a reduction in triglyceride levels at week 24Rate of primary end point by AF type and treatment group and HR foractive therapy vs placeboPatient group Placebo (%) Omega-3 PUFA (%) HR (95% CI) pParoxysmal AF* (n=542) 48 52 1.15 (0.90–1.46) 0.26Persistent AF (n=121) 33 50 1.64 (0.92–2.92) 0.09Any AF (all patients) 46 52 1.22 (0.98–1.52) 0.08
  • 4. P-OM3: Commentary*"There is no precedent for a drug that didnt work in the population we studiedworking in other populations, in atrial fibrillation. The fact that this drug failed in thispopulation, in my mind, makes it highly unlikely that youll see efficacy in othergroups." - Dr Peter R Kowey"There may be a lesson. . . . Maybe we have to test [supplements] just like we dodrugs." - Dr Robert Califf*All comments from Omega-3 PUFA caps dont suppress paroxysmal AF in randomized trial (http://www.theheart.org/article/1148957.do)
  • 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×